Table. Sample Characteristics.
| Characteristic | Participants, No. (%) | |||
|---|---|---|---|---|
| NEPTUNE | FSGS-CT | KRN | Pooled | |
| Study design | Prospective cohort | Randomized clinical trial | Electronic medical record–based registry | NA |
| Inclusion criteria | Incident FSGS enrolled at first kidney biopsy | Steroid-resistant FSGS | Prevalent FSGS patients | NA |
| Location | United States and Canada | United States and Canada | United States | NA |
| Enrollment | 2010-2019a | 2004-2008 | 2015-2019a | NA |
| Sample size, No. | 166 | 132 | 184 | 482 |
| Age, median (IQR), y | 30 (14-50) | 15 (11-23) | 22 (9-42) | 19 (12-38) |
| Children (age <13 y) | 32 (19) | 42 (32) | 53 (29) | 127 (26) |
| Adolescents (13-17 y) | 29 (17) | 48 (36) | 25 (14) | 102 (21) |
| Adults (≥18 y) | 105 (64) | 42 (32) | 106 (58) | 253 (52) |
| Sex | ||||
| Female | 67 (40) | 61 (46) | 87 (47) | 215 (45) |
| Male | 99 (60) | 71 (54) | 97 (53) | 258 (55) |
| Race and ethnicity | ||||
| Asian | 10 (6) | 3 (2) | 16 (9) | 29 (6) |
| Black | 60 (37) | 50 (38) | 28 (15) | 138 (29) |
| Native American or Pacific Islander | 0 | 2 (1) | 0 | 2 (<0.1) |
| White | 85 (54) | 75 (57) | 115 (63) | 275 (57) |
| Other | 4 (2) | 2 (1) | 21 (11) | 27 (6) |
| Unknown, No. | 7 | 0 | 0 | 7 |
| Hispanic ethnicity | 36 (22) | 23 (17) | 39 (21) | 98 (20) |
| APOL1 genotype | ||||
| 2 Risk alleles | 30 (20) | 25 (23) | NA | NA |
| 0-1 Risk alleles | 117 (80) | 86 (77) | NA | NA |
| Unknown, No. | 19 | 21 | 184 | 224 |
| Interstitial fibrosis, median (IQR), % | 15 (3-27) | 10 (4-25) | NA | NA |
| Global sclerosis, median (IQR), % | 10 (0-39) | 0 (0-12) | NA | NA |
| Segmental sclerosis, median (IQR), % | 7 (3-16) | 20 (9-33) | NA | NA |
| Baseline UP:C ratio, median (IQR), g/g | 3.8 (1.9-7.5) | 4.0 (2.2-8.4) | 4.0 (1.7-7.6) | 3.9 (1.9-7.6) |
| Baseline eGFR, median (IQR), mL/min/1.73 m2 | 72 (46-95) | 82 (60-116) | 64 (33-105) | 80 (54-105) |
| ESKD or 40% reduction in eGFR by year 3, % | ||||
| Children | 27 | 40 | 30 | 31 |
| Adolescents | 31 | 38 | 38 | 36 |
| Adults | 38 | 40 | 28 | 33 |
| ESKD by year 3, % | ||||
| Children | 0 | 13 | 13 | 11 |
| Adolescents | 0 | 22 | 21 | 16 |
| Adults | 12 | 23 | 24 | 20 |
| Complete remission by month 6, % | ||||
| Children | 22 | 32 | NA | 27 |
| Adolescents | 28 | 20 | NA | 22 |
| Adults | 16 | 10 | NA | 14 |
| Complete or partial remission by month 6, % | ||||
| Children | 55 | 56 | NA | 56 |
| Adolescents | 42 | 57 | NA | 52 |
| Adults | 44 | 62 | NA | 50 |
Abbreviations: eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; FSGS-CT, focal segmental glomerulosclerosis clinical trial; KRN, Kidney Research Network; NA, not applicable; NEPTUNE, Nephrotic Syndrome Study Network; UP:C, urine protein–to-creatinine.
a
Ongoing. Censored at 2019 for these analyses.